Artiva Biotherapeutics, Inc.: Artiva Announces Positive Initial Clinical Data with AlloNK Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 ...

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no pat ...

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid ...

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in ...

EU alignment ‘will not cut trade red tape’, claim experts

However, government claims the SPS deal would slash costs and red tape was significantly oversold, suggested Robert Hardy, ...